The FDA had approved Xarelto (rivaroxaban) in October 2018 and can be used to treat chronic angina in addition to beta-blockers, nitrates, calcium channel blockers, and ACE inhibitors. A changing regulatory scenario in the US and EU is expected to impact clinical trials of advanced therapy drugs. In Phase II / III studies, several gene therapy products are emerging as a novel approach to meet the need for non-surgical cardiovascular treatments. Taxus Cardium's DNA-based gene therapy with adenovector (serotype 5) is in a late clinical stage.

According to the report, High Awareness Level and Well-Established Health Care Facilities is one of the primary growth factors for the market. Demand for Disease-Modifying and Targeted Treatments is also expected to contribute significantly to the Angina Pectoris Drugs market. Overall, applications of Angina Pectoris Drugs, and the growing awareness of them, is what makes this segment of the industry important to its overall growth. The Distribution Channel, such as Hospital Pharmacy, is boosting the Angina Pectoris Drugs market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.The Angina Type, such as Stable Angina, is boosting the Angina Pectoris Drugs market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.The Diagnosis Type, such as EKG, is boosting the Angina Pectoris Drugs market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

AMA’s Analyst on the Global Angina Pectoris Drugs market identified that the demand is rising in many different parts of the world as "Initiatives Taken By the Government in the Emerging Countries to Promote Health Care ". Furthermore, some recent industry insights like "On April 15, 2020, Dr. Reddys Laboratories had announced the launch of an approved generic version of the Nitro-Dur transdermal infusion system (nitroglycerin). Nitro-Dur is used to prevent attacks of chest pain (angina pectoris) but does not treat angina pectoris that has already started." is constantly making the industry dynamic.

The report provides an in-depth analysis and forecast about the industry covering the following key features:
o Industry outlook including current and future market trends, drivers, restraints, and emerging technologies
o Analyses the Global Angina Pectoris Drugs market according to Type, Application, and regions
o Analyzes the top 10 players in terms of market reach, business strategy, and business focus
o Provides stakeholders’ insights and key drivers & trends of the market

Market Size Estimation
In market engineering method, both top-down and bottom-up approaches have been used, along with various data triangulation process, to predict and validate the market size of the Angina Pectoris Drugs market and other related sub-markets covered in the study.

o Key & emerging players in the market have been observed through secondary research.
o The industry’s supply chain and overall market size, in terms of value, have been derived through primary and secondary research processes.
o All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Check more with in-depth analysis and forecast of Angina Pectoris Drugs market study, Click here

Data Triangulation
The overall market size is calculated using market estimation process, the market was further split into various segments and sub-segments. To complete the overall market engineering and arriving at the exact statistics for all segments and sub-segments, the market breakdown and data triangulation procedures have been utilized, wherever applicable. The data have been triangulated by studying various influencing factors and trends identified from both demand and supply sides of various applications involved in the study. Along with this, the market size has been validated using both top-down and bottom-up approaches.